Organon & Co. (OGN) Projected to Post Quarterly Earnings on Thursday

Organon & Co. (NYSE:OGN - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 13th. Analysts expect Organon & Co. to post earnings of $0.92 per share and revenue of $1.59 billion for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.

Organon & Co. Stock Down 1.7 %

NYSE:OGN traded down $0.26 during trading hours on Friday, reaching $14.63. The company had a trading volume of 2,562,701 shares, compared to its average volume of 2,305,809. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm has a market cap of $3.77 billion, a price-to-earnings ratio of 2.90, a P/E/G ratio of 0.83 and a beta of 0.76. The business's 50-day simple moving average is $15.37 and its two-hundred day simple moving average is $17.66.

Analysts Set New Price Targets

Separately, TD Cowen upgraded Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.